Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults Pharmaceutical Investing
Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Pharmaceutical Investing
Veklury® Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies Pharmaceutical Investing
Universal Ibogaine Signs Memorandum of Understanding with the Osoyoos Indian Band Pharmaceutical Investing
AbbVie Announces First Provincial Reimbursements for VENCLEXTA® in Combination with Azacitidine for Acute Myeloid Leukemia Patients Pharmaceutical Investing
Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference Life Science Investing
Pivotal Phase 3 Data for KEYTRUDA® in High-Risk Early-Stage Triple-Negative Breast Cancer Published in the New England Journal of Medicine Pharmaceutical Investing
Johnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference Pharmaceutical Investing
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021 Pharmaceutical Investing
